Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783091 · ClinicalTrials.gov registry record · Phase 2
A Trial of Vitamin B12 in Septic Shock
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03783091 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 20 participants.
The verdict
NCT03783091, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will randomize 20 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to test the feasibility of completing clinical and laboratory protocols.
Interventions
- DRUG Placebo
- DRUG Hydroxocobalamin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03783091
The ClinicalTrials.gov registry entry for NCT03783091 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03783091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03783091 about?
NCT03783091 is a clinical study titled "A Trial of Vitamin B12 in Septic Shock". This study will randomize 20 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to test the feasibility of completing clinical and laboratory protocols.
What is the current status of trial NCT03783091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-08-05. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT03783091?
The interventions under investigation include: Placebo (DRUG), Hydroxocobalamin (DRUG).
Who is sponsoring clinical trial NCT03783091?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.